GoodRx Holdings, Inc.

NasdaqGS:GDRX Stock Report

Market Cap: US$1.7b

GoodRx Holdings Valuation

Is GDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GDRX ($4.44) is trading below our estimate of fair value ($12.76)

Significantly Below Fair Value: GDRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GDRX?

Key metric: As GDRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GDRX. This is calculated by dividing GDRX's market cap by their current revenue.
What is GDRX's PS Ratio?
PS Ratio2.2x
SalesUS$790.39m
Market CapUS$1.71b

Price to Sales Ratio vs Peers

How does GDRX's PS Ratio compare to its peers?

The above table shows the PS ratio for GDRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.7x
CERT Certara
4.6x9.6%US$1.7b
NXGN NextGen Healthcare
2.3x6.7%US$1.6b
TDOC Teladoc Health
0.6x0.7%US$1.6b
SDGR Schrödinger
7.3x18.9%US$1.4b
GDRX GoodRx Holdings
2.2x5.9%US$1.7b

Price-To-Sales vs Peers: GDRX is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does GDRX's PS Ratio compare vs other companies in the US Healthcare Services Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
MPLN MultiPlan
0.1x1.7%US$97.35m
HCTI Healthcare Triangle
0.3xn/aUS$4.65m
ICCT iCoreConnect
0.3xn/aUS$2.90m
ISPC iSpecimen
0.3xn/aUS$2.89m
GDRX 2.2xIndustry Avg. 2.2xNo. of Companies11PS01.63.24.86.48+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GDRX is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is GDRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GDRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio5.1x

Price-To-Sales vs Fair Ratio: GDRX is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (5.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GDRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.44
US$7.15
+61.0%
23.1%US$10.00US$4.50n/a17
Dec ’25US$4.84
US$7.34
+51.7%
21.5%US$10.00US$4.50n/a16
Nov ’25US$6.19
US$9.47
+53.0%
23.3%US$16.00US$5.00n/a17
Oct ’25US$6.93
US$9.56
+37.9%
22.7%US$16.00US$5.00n/a18
Sep ’25US$7.90
US$9.56
+21.0%
22.7%US$16.00US$5.00n/a18
Aug ’25US$8.75
US$9.60
+9.7%
22.4%US$16.00US$5.00n/a18
Jul ’25US$7.82
US$9.51
+21.7%
22.3%US$16.00US$5.00n/a19
Jun ’25US$7.87
US$9.33
+18.5%
23.3%US$16.00US$5.00n/a19
May ’25US$6.97
US$8.68
+24.5%
22.5%US$14.00US$5.00n/a19
Apr ’25US$7.10
US$8.66
+22.0%
23.2%US$14.00US$5.00n/a18
Mar ’25US$8.35
US$8.44
+1.1%
24.6%US$14.00US$5.00n/a17
Feb ’25US$6.13
US$7.09
+15.7%
24.6%US$12.00US$4.50n/a16
Jan ’25US$6.70
US$6.90
+3.0%
26.5%US$12.00US$5.00n/a15
Dec ’24US$6.37
US$6.72
+5.5%
26.7%US$12.00US$5.00US$4.8416
Nov ’24US$5.04
US$8.67
+72.0%
17.6%US$12.00US$7.00US$6.1915
Oct ’24US$5.63
US$8.63
+53.2%
17.2%US$12.00US$7.00US$6.9316
Sep ’24US$6.55
US$8.39
+28.1%
19.0%US$12.00US$6.00US$7.9018
Aug ’24US$8.67
US$6.79
-21.7%
23.1%US$12.00US$5.00US$8.7518
Jul ’24US$5.52
US$6.41
+16.1%
14.2%US$8.00US$5.00US$7.8219
Jun ’24US$5.37
US$6.41
+19.3%
14.2%US$8.00US$5.00US$7.8719
May ’24US$4.58
US$6.95
+51.7%
13.8%US$9.00US$6.00US$6.9719
Apr ’24US$6.25
US$6.95
+11.2%
13.8%US$9.00US$6.00US$7.1019
Mar ’24US$5.50
US$6.92
+25.8%
14.5%US$9.00US$6.00US$8.3519
Feb ’24US$5.91
US$6.97
+18.0%
20.5%US$10.00US$4.50US$6.1319
Jan ’24US$4.66
US$7.13
+53.0%
23.5%US$11.00US$4.50US$6.7019
Dec ’23US$5.16
US$7.13
+38.2%
23.5%US$11.00US$4.50US$6.3719

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GoodRx Holdings, Inc. is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Ishan MajumdarBaptista Research
Michael ChernyBofA Global Research